51
|
Hu H, Dong Y, Li M, Wang R, Zhang X, Gong P, Zhao Y. Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents. Bioorg Chem 2019; 90:103086. [DOI: 10.1016/j.bioorg.2019.103086] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 06/21/2019] [Accepted: 06/25/2019] [Indexed: 02/05/2023]
|
52
|
Hajra S, Hazra A, Abu Saleh SK. One-Pot Synthesis of Enantiopure Spiro[3,4-dihydrobenzo[ b][1,4]oxazine-2,3'-oxindole] via Regio- and Stereoselective Tandem Ring Opening/Cyclization of Spiroaziridine Oxindoles with Bromophenols. J Org Chem 2019; 84:10412-10421. [PMID: 31309826 DOI: 10.1021/acs.joc.9b01611] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
A highly efficient regio- and stereoselective spiroaziridine ring opening with 2-bromophenols and a subsequent tandem cyclization reaction was developed for the one-pot synthesis of enantiopure 3,4-dihydrospiro[benzo[b][1,4]oxazine-2,3'-oxindole] with excellent enantiopurity (ee up to >99%). It is further extended to asymmetric synthesis of NH-free 3,4-dihydrospiro[benzo[b][1,4]oxazine-2,3'-xindole] retaining the optical activity.
Collapse
Affiliation(s)
- Saumen Hajra
- Centre of Biomedical Research , Sanjay Gandhi Post-Graduate Institute of Medical Sciences Campus , Raebareli Road , Lucknow 226014 , India
| | - Atanu Hazra
- Centre of Biomedical Research , Sanjay Gandhi Post-Graduate Institute of Medical Sciences Campus , Raebareli Road , Lucknow 226014 , India
| | - S K Abu Saleh
- Centre of Biomedical Research , Sanjay Gandhi Post-Graduate Institute of Medical Sciences Campus , Raebareli Road , Lucknow 226014 , India
| |
Collapse
|
53
|
Hobbs H, Bravi G, Campbell I, Convery M, Davies H, Inglis G, Pal S, Peace S, Redmond J, Summers D. Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway. J Med Chem 2019; 62:6972-6984. [PMID: 31283227 DOI: 10.1021/acs.jmedchem.9b00348] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
4-(Pyrimidin-4-yl)morpholines are privileged pharmacophores for PI3K and PIKKs inhibition by virtue of the morpholine oxygen, both forming the key hydrogen bonding interaction and conveying selectivity over the broader kinome. Key to the morpholine utility as a kinase hinge binder is its ability to adopt a coplanar conformation with an adjacent aromatic core favored by the morpholine nitrogen nonbonding pair of electrons interacting with the electron deficient pyrimidine π-system. Few selective morpholine replacements have been identified to date. Herein we describe the discovery of a potent non-nitrogen containing morpholine isostere with the ability to mimic this conformation and its application in a potent selective dual inhibitor of mTORC1 and mTORC2 (29b).
Collapse
Affiliation(s)
- Heather Hobbs
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Gianpaolo Bravi
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Ian Campbell
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Maire Convery
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Hannah Davies
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Graham Inglis
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Sandeep Pal
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Simon Peace
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Joanna Redmond
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Declan Summers
- GlaxoSmithKline R&D , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| |
Collapse
|
54
|
Janockova J, Korabecny J, Plsikova J, Babkova K, Konkolova E, Kucerova D, Vargova J, Koval J, Jendzelovsky R, Fedorocko P, Kasparkova J, Brabec V, Rosocha J, Soukup O, Hamulakova S, Kuca K, Kozurkova M. In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers. J Enzyme Inhib Med Chem 2019; 34:877-897. [PMID: 30938202 PMCID: PMC6450562 DOI: 10.1080/14756366.2019.1593159] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
A combination of biochemical, biophysical and biological techniques was used to study calf thymus DNA interaction with newly synthesized 7-MEOTA-tacrine thiourea 12-17 and urea heterodimers 18-22, and to measure interference with type I and II topoisomerases. Their biological profile was also inspected in vitro on the HL-60 cell line using different flow cytometric techniques (cell cycle distribution, detection of mitochondrial membrane potential dissipation, and analysis of metabolic activity/viability). The compounds exhibited a profound inhibitory effect on topoisomerase activity (e.g. compound 22 inhibited type I topoisomerase at 1 µM concentration). The treatment of HL-60 cells with the studied compounds showed inhibition of cell growth especially with hybrids containing thiourea (14-17) and urea moieties (21 and 22). Moreover, treatment of human dermal fibroblasts with the studied compounds did not indicate significant cytotoxicity. The observed results suggest beneficial selectivity of the heterodimers as potential drugs to target cancer cells.
Collapse
Affiliation(s)
- Jana Janockova
- a Department of Biochemistry, Institute of Chemistry, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic.,b Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Jan Korabecny
- b Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Jana Plsikova
- a Department of Biochemistry, Institute of Chemistry, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic.,d Associated Tissue Bank, Faculty of Medicine , P.J. Šafárik University , Kosice , Slovak Republic
| | - Katerina Babkova
- b Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Eva Konkolova
- a Department of Biochemistry, Institute of Chemistry, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Dana Kucerova
- e Department of Cellular Biology, Institute of Biology and Ecology, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Jana Vargova
- e Department of Cellular Biology, Institute of Biology and Ecology, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Jan Koval
- e Department of Cellular Biology, Institute of Biology and Ecology, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Rastislav Jendzelovsky
- e Department of Cellular Biology, Institute of Biology and Ecology, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Peter Fedorocko
- e Department of Cellular Biology, Institute of Biology and Ecology, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Jana Kasparkova
- f Department of Biophysics, Faculty of Science , Palacke University , Olomouc , Czech Republic
| | - Viktor Brabec
- f Department of Biophysics, Faculty of Science , Palacke University , Olomouc , Czech Republic
| | - Jan Rosocha
- d Associated Tissue Bank, Faculty of Medicine , P.J. Šafárik University , Kosice , Slovak Republic
| | - Ondrej Soukup
- b Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Slavka Hamulakova
- g Department of Organic Chemistry, Institute of Chemistry, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic
| | - Kamil Kuca
- b Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Maria Kozurkova
- a Department of Biochemistry, Institute of Chemistry, Faculty of Science , P. J. Šafárik University , Kosice , Slovak Republic.,b Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| |
Collapse
|
55
|
Reinecke M, Ruprecht B, Poser S, Wiechmann S, Wilhelm M, Heinzlmeir S, Kuster B, Médard G. Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors. ACS Chem Biol 2019; 14:655-664. [PMID: 30901187 DOI: 10.1021/acschembio.8b01020] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Chemical proteomic approaches utilizing immobilized, broad-selective kinase inhibitors (Kinobeads) have proven valuable for the elucidation of a compound's target profile under close-to-physiological conditions and often revealed potentially synergistic or toxic off-targets. Current Kinobeads enrich more than 300 native protein kinases from cell line or tissue lysates but do not systematically cover phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related kinases (PIKKs). Some PIKKs and PI3Ks show aberrant activation in many human diseases and are indeed validated drug targets. Here, we report the development of a novel version of Kinobeads that extends kinome coverage to these proteins. This is achieved by inclusion of two affinity probes derived from the clinical PI3K/MTOR inhibitors Omipalisib and BGT226. We demonstrate the utility of the new affinity matrix by the profiling of 13 clinical and preclinical PIKK/PI3K inhibitors. The large discrepancies between the PI3K affinity values obtained and reported results from recombinant assays led us to perform a phosphoproteomic experiment showing that the chemoproteomic assay is the better approximation of PI3K inhibitor action in cellulo. The results further show that NVP-BEZ235 is not a PI3K inhibitor. Surprisingly, the designated ATM inhibitor CP466722 was found to bind strongly to ALK2, identifying a new chemotype for drug discovery to treat fibrodysplasia ossificans progressiva.
Collapse
Affiliation(s)
- Maria Reinecke
- German Cancer Consortium
(DKTK), Munich, Germany
- German
Cancer
Research Center (DKFZ), Heidelberg, Germany
| | - Benjamin Ruprecht
- Center for Integrated
Protein Science Munich (CIPSM), Freising, Germany
| | | | - Svenja Wiechmann
- German Cancer Consortium
(DKTK), Munich, Germany
- German
Cancer
Research Center (DKFZ), Heidelberg, Germany
| | | | | | - Bernhard Kuster
- German Cancer Consortium
(DKTK), Munich, Germany
- German
Cancer
Research Center (DKFZ), Heidelberg, Germany
- Center for Integrated
Protein Science Munich (CIPSM), Freising, Germany
| | | |
Collapse
|
56
|
Montané MH, Menand B. TOR inhibitors: from mammalian outcomes to pharmacogenetics in plants and algae. JOURNAL OF EXPERIMENTAL BOTANY 2019; 70:2297-2312. [PMID: 30773593 DOI: 10.1093/jxb/erz053] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 02/05/2019] [Indexed: 05/19/2023]
Abstract
Target of rapamycin (TOR) is a conserved eukaryotic phosphatidylinositol 3-kinase-related kinase that regulates growth and metabolism in response to environment in plants and algae. The study of the plant and algal TOR pathway has largely depended on TOR inhibitors first developed for non-photosynthetic eukaryotes. In animals and yeast, fundamental work on the TOR pathway has benefited from the allosteric TOR inhibitor rapamycin and more recently from ATP-competitive TOR inhibitors (asTORis) that circumvent the limitations of rapamycin. The asTORis, developed for medical application, inhibit TOR complex 1 (TORC1) more efficiently than rapamycin and also inhibit rapamycin-resistant TORCs. This review presents knowledge on TOR inhibitors from the mammalian field and underlines important considerations for plant and algal biologists. It discusses the use of rapamycin and asTORis in plants and algae and concludes with guidelines for physiological studies and genetic screens with TOR inhibitors.
Collapse
Affiliation(s)
- Marie-Hélène Montané
- Aix Marseille Université, CEA, CNRS, BIAM, Laboratoire de génétique et biophysique des plantes, Marseille, F-13009, France
| | - Benoît Menand
- Aix Marseille Université, CEA, CNRS, BIAM, Laboratoire de génétique et biophysique des plantes, Marseille, F-13009, France
| |
Collapse
|
57
|
Conway JRW, Herrmann D, Evans TRJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019; 68:742-758. [PMID: 30396902 PMCID: PMC6580874 DOI: 10.1136/gutjnl-2018-316822] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 10/02/2018] [Accepted: 10/04/2018] [Indexed: 12/16/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly solid tumours. This is due to a generally late-stage diagnosis of a primarily treatment-refractory disease. Several large-scale sequencing and mass spectrometry approaches have identified key drivers of this disease and in doing so highlighted the vast heterogeneity of lower frequency mutations that make clinical trials of targeted agents in unselected patients increasingly futile. There is a clear need for improved biomarkers to guide effective targeted therapies, with biomarker-driven clinical trials for personalised medicine becoming increasingly common in several cancers. Interestingly, many of the aberrant signalling pathways in PDAC rely on downstream signal transduction through the mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K) pathways, which has led to the development of several approaches to target these key regulators, primarily as combination therapies. The following review discusses the trend of PDAC therapy towards molecular subtyping for biomarker-driven personalised therapies, highlighting the key pathways under investigation and their relationship to the PI3K pathway.
Collapse
Affiliation(s)
- James RW Conway
- Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia
| | - David Herrmann
- Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia
- St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - TR Jeffry Evans
- Cancer Department, Cancer Research UK Beatson Institute, Glasgow, UK
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Jennifer P Morton
- Cancer Department, Cancer Research UK Beatson Institute, Glasgow, UK
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Paul Timpson
- Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia
- St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| |
Collapse
|
58
|
de Jong J, Heijnen D, Helbert H, Feringa BL. One-pot, modular approach to functionalized ketones via nucleophilic addition/Buchwald-Hartwig amination strategy. Chem Commun (Camb) 2019; 55:2908-2911. [PMID: 30785130 DOI: 10.1039/c8cc08444k] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A general one-pot procedure for the 1,2-addition of organolithium reagents to amides followed by the Buchwald-Hartwig amination with in situ released lithium amides is presented. In this work amides are used as masked ketones, revealed by the addition of organolithium reagents which generates a lithium amide, suitable for subsequent Buchwald-Hartwig coupling in the presence of a palladium catalyst. This methodology allows for rapid, efficient and atom economic synthesis of aminoarylketones in good yields.
Collapse
Affiliation(s)
- Jorn de Jong
- Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands.
| | - Dorus Heijnen
- Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands.
| | - Hugo Helbert
- Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands.
| | - Ben L Feringa
- Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands.
| |
Collapse
|
59
|
Novel quinazolin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity. Bioorg Chem 2019; 82:204-210. [DOI: 10.1016/j.bioorg.2018.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Revised: 10/01/2018] [Accepted: 10/02/2018] [Indexed: 12/14/2022]
|
60
|
Perry MWD, Abdulai R, Mogemark M, Petersen J, Thomas MJ, Valastro B, Westin Eriksson A. Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. J Med Chem 2018; 62:4783-4814. [DOI: 10.1021/acs.jmedchem.8b01298] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
| | - Raolat Abdulai
- Respiratory, Inflammation & Autoimmunity Translational Medicine Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts 02451, United States
- Brigham and Women’s Hospital, Boston, Massachusetts 02115, United States
| | | | | | | | | | | |
Collapse
|
61
|
Garces AE, Stocks MJ. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. J Med Chem 2018; 62:4815-4850. [DOI: 10.1021/acs.jmedchem.8b01492] [Citation(s) in RCA: 83] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Aimie E. Garces
- Centre for Biomolecular Sciences, University Park Nottingham, Nottingham NG7 2RD, U.K
| | - Michael J. Stocks
- Centre for Biomolecular Sciences, University Park Nottingham, Nottingham NG7 2RD, U.K
| |
Collapse
|
62
|
Barton N, Convery M, Cooper AWJ, Down K, Hamblin JN, Inglis G, Peace S, Rowedder J, Rowland P, Taylor JA, Wellaway N. Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth Approach. J Med Chem 2018; 61:11061-11073. [PMID: 30532965 DOI: 10.1021/acs.jmedchem.8b01556] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A deconstruction of previously reported phosphoinositide 3-kinase δ (PI3Kδ) inhibitors and subsequent regrowth led to the identification of a privileged fragment for PI3Kδ, which was exploited to deliver a potent, efficient, and selective lead series with a novel binding mode observed in the PI3Kδ crystal structure.
Collapse
Affiliation(s)
- Nick Barton
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Máire Convery
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Anthony W J Cooper
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Kenneth Down
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - J Nicole Hamblin
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Graham Inglis
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Simon Peace
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - James Rowedder
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Paul Rowland
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Jonathan A Taylor
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| | - Natalie Wellaway
- GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K
| |
Collapse
|
63
|
Heppell JT, Islam MA, McAlpine SR, Al‐Rawi JMA. Functionalization of Quinazolin‐4‐ones Part 3: Synthesis, Structures Elucidation, DNA‐PK, PI3K, and Cytotoxicity of Novel 8‐Aryl‐2‐morpholino‐quinazolin‐4‐ones. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3385] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Jacob T. Heppell
- Department of Pharmacy and Applied ScienceLa Trobe Institute for Molecular Science, La Trobe University Bendigo P.O. Box 199 Bendigo Victoria 3550 Australia
| | - Md. Amirul Islam
- School of ChemistryUniversity of New South Wales Sydney New South Wales 2052 Australia
| | - Shelli R. McAlpine
- School of ChemistryUniversity of New South Wales Sydney New South Wales 2052 Australia
| | - Jasim M. A. Al‐Rawi
- Department of Pharmacy and Applied ScienceLa Trobe Institute for Molecular Science, La Trobe University Bendigo P.O. Box 199 Bendigo Victoria 3550 Australia
| |
Collapse
|
64
|
Luan Y, Li J, Bernatchez JA, Li R. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. J Med Chem 2018; 62:3171-3183. [PMID: 30418766 DOI: 10.1021/acs.jmedchem.8b00189] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. It has been well validated that an agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and in potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDAC inhibitor. In this perspective, the authors review the majority of reported kinase/HDAC hybrid inhibitors.
Collapse
Affiliation(s)
- Yepeng Luan
- Department of Medicinal Chemistry, School of Pharmacy , Qingdao University , Qingdao 266071 , Shandong Province , China
| | | | | | - Rongshi Li
- Department of Medicinal Chemistry, School of Pharmacy , Qingdao University , Qingdao 266071 , Shandong Province , China.,UNMC Center for Drug Discovery, Department of Pharmaceutical Sciences, College of Pharmacy, Fred and Pamela Buffett Cancer Center, and Center for Staphylococcal Research , University of Nebraska Medical Center , Omaha , Nebraska 68198 , United States
| |
Collapse
|
65
|
Abdel-Maksoud MS, El-Gamal MI, Benhalilou DR, Ashraf S, Mohammed SA, Oh CH. Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors. Med Res Rev 2018; 39:631-664. [PMID: 30251347 DOI: 10.1002/med.21535] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Revised: 07/31/2018] [Accepted: 08/01/2018] [Indexed: 12/23/2022]
Abstract
The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.
Collapse
Affiliation(s)
- Mohammed S Abdel-Maksoud
- Medicinal & Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Giza, Egypt
| | - Mohammed I El-Gamal
- Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.,Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, Egypt
| | - Dalia Reyane Benhalilou
- Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates
| | - Sandy Ashraf
- Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates
| | | | - Chang-Hyun Oh
- Center for Biomaterials, Korea Institute of Science and Technology, Seoul, Korea.,Department of Biomolecular Science, University of Science and Technology, Daejeon, Korea
| |
Collapse
|
66
|
Degorce SL, Bodnarchuk MS, Cumming IA, Scott JS. Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines. J Med Chem 2018; 61:8934-8943. [PMID: 30189136 DOI: 10.1021/acs.jmedchem.8b01148] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In this article, we report our investigation of a phenomenon by which bridging morpholines across the ring with one-carbon tethers leads to a counterintuitive reduction in lipophilicity. This effect was also found to occur in piperazines and piperidines and lowered the measured log D7.4 of the bridged molecules by as much as -0.8 relative to their unbridged counterparts. As lowering lipophilicity without introducing additional heteroatoms can be desirable, we believe this potentially provides a useful tactic to improve the drug-like properties of molecules containing morpholine-, piperazine-, and piperidine-like motifs.
Collapse
Affiliation(s)
- Sébastien L Degorce
- Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom
| | - Michael S Bodnarchuk
- Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom
| | - Iain A Cumming
- Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom
| | - James S Scott
- Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom
| |
Collapse
|
67
|
Purin-6-one and pyrrolo[2,3-d]pyrimidin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity. Future Med Chem 2018; 10:2029-2038. [PMID: 30067076 DOI: 10.4155/fmc-2018-0086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
AIM DNA damage response plays an eminent role in patients' response to conventional chemotherapy and radiotherapy. Its inhibition is of great interest as it can overcome cancer cell resistance and reduce the effective doses of DNA damaging agents. Results & methodology: We have focused our research on phosphatidylinositol 3-kinase-related kinases and prepared 35 novel compounds through a scaffold hopping approach. The newly synthesized inhibitors were tested on a panel of nine cancer and one healthy cell lines alone and in combination with appropriate doses of doxorubicin. CONCLUSION Five novel compounds 4f, 10b, 15g, 7e and 15f in combination with doxorubicin showed significant antiproliferative effect on seven cancer cell lines while not affecting the cell growth alone.
Collapse
|
68
|
Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors. Bioorg Med Chem 2018; 26:3982-3991. [DOI: 10.1016/j.bmc.2018.06.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 06/13/2018] [Accepted: 06/15/2018] [Indexed: 02/08/2023]
|
69
|
Shen S, He X, Yang Z, Zhang L, Liu Y, Zhang Z, Wang W, Liu W, Li Y, Huang D, Sun K, Ni X, Yang X, Chu X, Cui Y, Lv Q, Lan J, Zhou F. Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines. ACS Med Chem Lett 2018; 9:719-724. [PMID: 30034607 DOI: 10.1021/acsmedchemlett.8b00167] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 06/25/2018] [Indexed: 12/20/2022] Open
Abstract
The discovery and optimization of a series of 2-morpholino-pyrimidine derivatives containing various sulfonyl side chains at the C4 position led to the identification of compound 26 as a potent dual PI3K/mTOR inhibitor. It exhibited high inhibitory activity against PI3Kα/β/γ/δ (IC50 = 20/376/204/46 nM) and mTOR (IC50 = 189 nM), potent functional suppression of AKT phosphorylation (IC50 = 196 nM), and excellent antiproliferative effects on a panel of cancer cells. Enzymic data and modeling simulation indicate that a cyclopropyl ring on the C4 sulfone chain and a fluorine on the C6 aminopyridyl moiety are responsible for its maintained PI3K activity and enhanced mTOR potency, respectively. Furthermore, compound 26 exhibited higher efficiency in the HT-29 colorectal carcinoma xenograft model at the daily dose of 3.75 and 7.5 mg/kg relative to BKM120 at the dose of 15 and 30 mg/kg.
Collapse
Affiliation(s)
- Sida Shen
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Xiangyu He
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Zheng Yang
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Liang Zhang
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Yingtao Liu
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Zhiyuan Zhang
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Weiwei Wang
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Wei Liu
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Yufeng Li
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Dong Huang
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Kai Sun
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Xiaojing Ni
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Xu Yang
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Xinxin Chu
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Yumin Cui
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Qiang Lv
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Jiong Lan
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| | - Fusheng Zhou
- Yangtze River Pharmaceutical Group, Shanghai Haiyan Pharmaceutical Technology Co. Ltd., No. 8, 67 Libing Road, Shanghai 201203, China
| |
Collapse
|
70
|
Synthesis and PI3 Kinase Inhibition Activity of Some Novel Trisubstituted Morpholinopyrimidines. Molecules 2018; 23:molecules23071675. [PMID: 29996482 PMCID: PMC6100461 DOI: 10.3390/molecules23071675] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 07/05/2018] [Accepted: 07/07/2018] [Indexed: 11/17/2022] Open
Abstract
A number of new substituted morpholinopyrimidines were prepared utilizing sequential nucleophilic aromatic substitution and cross-coupling reactions. One of the disubstituted pyrimidines was converted into two trisubstituted compounds which were screened as PI3K inhibitors relative to the well-characterized PI3K inhibitor ZSTK474, and were found to be 1.5⁻3-times more potent. A leucine linker was attached to the most active inhibitor since it would remain on any peptide-containing prodrug after cleavage by prostate-specific antigen, and it did not prevent inhibition of AKT phosphorylation and hence the inhibition of PI3K by the modified inhibitor.
Collapse
|
71
|
Synthesis and PI 3-Kinase Inhibition Activity of Some Novel 2,4,6-Trisubstituted 1,3,5-Triazines. Molecules 2018; 23:molecules23071628. [PMID: 29973512 PMCID: PMC6100378 DOI: 10.3390/molecules23071628] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 06/30/2018] [Accepted: 07/02/2018] [Indexed: 01/20/2023] Open
Abstract
A number of new trisubstituted triazine phosphatidylinositol 3-kinase (PI3K) inhibitors were prepared via a three-step procedure utilizing sequential nucleophilic aromatic substitution and cross-coupling reactions. All were screened as PI3K inhibitors relative to the well-characterized PI3K inhibitor, ZSTK474. The most active inhibitors prepared here were 2–4 times more potent than ZSTK474. A leucine linker was attached to the most active inhibitor since it would remain on any peptide-containing prodrug after cleavage by a prostate-specific antigen, and it did not prevent inhibition of protein kinase B (Akt) phosphorylation, and hence, the inhibition of PI3K by the modified inhibitor.
Collapse
|
72
|
Aggile K, Alagumuthu M, Mundre RS, Napoleon AA. Synthesis of Substituted Quinolinyl Ether-based Inhibitors of PI3K as Potential Anticancer Agents. J Heterocycl Chem 2018. [DOI: 10.1002/jhet.3202] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Kadirappa Aggile
- School of Advanced Sciences, Department of Chemistry; VIT University; Vellore Tamil Nadu 632014 India
- Chemical Research Department, API R&D Centre; Micro Labs Ltd; Bommasandra Bangalore Karnataka 560105 India
| | - Manikandan Alagumuthu
- Department of Biotechnology, School of Bio-Science and Technology; VIT University; Vellore Tamil Nadu 632014 India
| | | | | |
Collapse
|
73
|
Xiao YS, Zhang B, Zhang M, Guo ZK, Deng XZ, Shi J, Li W, Jiao RH, Tan RX, Ge HM. Rifamorpholines A-E, potential antibiotics from locust-associated actinobacteria Amycolatopsis sp. Hca4. Org Biomol Chem 2018; 15:3909-3916. [PMID: 28422262 DOI: 10.1039/c7ob00614d] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Cultivation of locust associated rare actinobacteria, Amycolatopsis sp. HCa4, has provided five unusual macrolactams rifamorpholines A-E. Their structures were determined by interpretation of spectroscopic and crystallographic data. Rifamorpholines A-E possess an unprecedented 5/6/6/6 ring chromophore, representing a new subclass of rifamycin antibiotics. The biosynthetic pathway for compounds 1-5 involves a key 1,6-cyclization for the formation of the morpholine ring. Compounds 2 and 4 showed potent activities against methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 4.0 and 8.0 μM, respectively.
Collapse
Affiliation(s)
- Yong Sheng Xiao
- State Key Laboratory of Pharmaceutical Biotechnology, Institute of Functional Biomolecules, School of Life Sciences, Nanjing University, 163 Xianlin Avenue, Nanjing 210046, China.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
74
|
McGivern T, Afsharpour S, Marmion C. Copper complexes as artificial DNA metallonucleases: From Sigman’s reagent to next generation anti-cancer agent? Inorganica Chim Acta 2018. [DOI: 10.1016/j.ica.2017.08.043] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
75
|
Antolin AA, Tym JE, Komianou A, Collins I, Workman P, Al-Lazikani B. Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chem Biol 2018; 25:194-205.e5. [PMID: 29249694 PMCID: PMC5814752 DOI: 10.1016/j.chembiol.2017.11.004] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 09/22/2017] [Accepted: 11/14/2017] [Indexed: 12/21/2022]
Abstract
Chemical probes are essential tools for understanding biological systems and for target validation, yet selecting probes for biomedical research is rarely based on objective assessment of all potential compounds. Here, we describe the Probe Miner: Chemical Probes Objective Assessment resource, capitalizing on the plethora of public medicinal chemistry data to empower quantitative, objective, data-driven evaluation of chemical probes. We assess >1.8 million compounds for their suitability as chemical tools against 2,220 human targets and dissect the biases and limitations encountered. Probe Miner represents a valuable resource to aid the identification of potential chemical probes, particularly when used alongside expert curation.
Collapse
Affiliation(s)
- Albert A Antolin
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK; Department of Data Science, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK
| | - Joseph E Tym
- Department of Data Science, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK
| | - Angeliki Komianou
- Department of Data Science, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK
| | - Ian Collins
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK
| | - Paul Workman
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK.
| | - Bissan Al-Lazikani
- Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK; Department of Data Science, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, UK.
| |
Collapse
|
76
|
Chen D, Soh CK, Goh WH, Wang H. Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. J Med Chem 2018; 61:1552-1575. [DOI: 10.1021/acs.jmedchem.7b01465] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Dizhong Chen
- Drug Development
Unit, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore
| | - Chang Kai Soh
- Drug Development
Unit, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore
| | - Wei Huang Goh
- Drug Development
Unit, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore
| | - Haishan Wang
- Drug Development
Unit, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore
- Probit Pharmaceuticals Pte. Ltd., 10 Anson Road no. 26-04, Singapore 079903, Republic of Singapore
| |
Collapse
|
77
|
Ďurišová K, Čecháková L, Jošt P, Šinkorová Z, Kmochová A, Pejchal J, Ondrej M, Vávrová J, Tichý A. DNA repair inhibitors as radiosensitizers in human lung cells. J Appl Biomed 2018. [DOI: 10.1016/j.jab.2017.10.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
78
|
Parveen H, Alsharif MA, Alahmdi MI, Mukhtar S, Azam A. Novel Pyrimidine-based Ferrocenyl substituted Organometallic Compounds: Synthesis, Characterization and Biological Evaluation. Appl Organomet Chem 2018. [DOI: 10.1002/aoc.4261] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Humaira Parveen
- Department of Chemistry, Faculty of Science; University of Tabuk; Tabuk 71491 Kingdom of Saudi Arabia
| | - Meshari A. Alsharif
- Department of Chemistry, Faculty of Science; University of Tabuk; Tabuk 71491 Kingdom of Saudi Arabia
| | - Mohammed I. Alahmdi
- Department of Chemistry, Faculty of Science; University of Tabuk; Tabuk 71491 Kingdom of Saudi Arabia
| | - Sayeed Mukhtar
- Department of Chemistry, Faculty of Science; University of Tabuk; Tabuk 71491 Kingdom of Saudi Arabia
| | - Amir Azam
- Department of Chemistry; Jamia Millia Islamia; Jamia Nagar New Delhi 110025 India
| |
Collapse
|
79
|
Arjmand F, Afsan Z, Roisnel T. Design, synthesis and characterization of novel chromone based-copper(ii) antitumor agents with N,N-donor ligands: comparative DNA/RNA binding profile and cytotoxicity. RSC Adv 2018; 8:37375-37390. [PMID: 35557803 PMCID: PMC9089433 DOI: 10.1039/c8ra06722h] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 10/23/2018] [Indexed: 01/05/2023] Open
Abstract
A series of new chromone based-Cu(ii) complexes 1–3 derived from bioactive pharmacophore, 3-formylchromone and N,N-donor ligands viz., 1,10-phenanthroline, 2,2′-bipyridine and 1R,2R-DACH were synthesized as potential antitumor agents and thoroughly characterized by UV-vis, FT-IR, EPR, ESI-MS and elemental analysis. Single X-crystal diffraction studies of complex 2 revealed triclinic P1̄ space group with square pyramidal geometry around the Cu(ii) center. Comparative in vitro binding studies with ct-DNA and tRNA were carried out using absorption and emission titration experiments which revealed intercalative mode of binding with higher binding propensity of complexes 1–3 towards tRNA as compared to ct-DNA. Additionally, complex 1 exhibited high binding affinity among all the three complexes due to the involvement of phen co-ligands via π-stacking interactions in between nucleic acid base pairs. Furthermore, Hirshfeld surface analysis was carried out for complex 2 to investigate various intra and intermolecular non-covalent interactions (H-bonding, C–H⋯π etc.) accountable for stabilization of crystal lattice. The cleavage activity of complex 1 was performed by gel electrophoretic assay with pBR322 DNA and tRNA which revealed efficient DNA/tRNA cleaving ability of complex, suggesting tRNA cleavage both concentration and time dependent. Furthermore, in vitro cytotoxic activity of complexes 1–3 on a selected panel of human cancer cell lines was performed which revealed that all three complexes exhibited remarkably good cytotoxic activity with GI50 value < 10 μg mL−1 (<20 μM). New chromone-based Cu(ii) tRNA targeted complexes 1–3 as potential anticancer agents have been synthesized and thoroughly characterized.![]()
Collapse
Affiliation(s)
- Farukh Arjmand
- Department of Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| | - Zeenat Afsan
- Department of Chemistry
- Aligarh Muslim University
- Aligarh 202002
- India
| | - Thierry Roisnel
- Institut des Sciences Chimiques de Rennes
- UMR 6226, Université de Rennes 1
- 15335042 Rennes
- France
| |
Collapse
|
80
|
Bakthadoss M, Meegada SK, Surendar M. Triple domino reaction for the synthesis of pyrazole/indoline linked chromenes. Tetrahedron 2018. [DOI: 10.1016/j.tet.2017.12.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
81
|
Li W, Sun Q, Song L, Gao C, Liu F, Chen Y, Jiang Y. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings. Eur J Med Chem 2017; 141:721-733. [PMID: 29107429 DOI: 10.1016/j.ejmech.2017.09.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2017] [Revised: 08/31/2017] [Accepted: 09/02/2017] [Indexed: 12/19/2022]
Abstract
PI3K/Akt/mTOR and hedgehog (Hh) signalings are two important pathways in breast cancer, which are usually connected with the drug resistance and cancer migration. Many studies indicated that PI3K/Akt/mTOR inhibitors and Hh inhibitors displayed synergistic effects, and the combination of the two signaling drugs could delay drug resistance and inhibit cancer migration in breast cancer. Therefore, the development of molecules simultaneously inhibiting these two pathways is urgent needed. Based on the structures of PI3K inhibitor buparlisib and Hh inhibitor vismodegib, a series of hybrid structures were designed and synthesized utilizing rational drug design and computer-based drug design. Several compounds displayed excellent antiproliferative activities against several breast cancer cell lines, including triple-negative breast cancer (TNBC) MDA-MB-231 cell. Further mechanistic studies demonstrated that the representative compound 9i could inhibit both PI3K/Akt/mTOR and hedgehog (Hh) signalings by inhibiting the phosphorylation of S6K and Akt as well as decreasing the SAG elevated expression of Gli1. Compound 9i could also induce apoptosis remarkably in T47D and MDA-MB-231 cells. In the transwell assay, 9i showed significant inhibition on the migration of MDA-MB-231.
Collapse
Affiliation(s)
- Wenlu Li
- Department of Chemistry, Tsinghua University, Beijing 100084, PR China; The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
| | - Qinsheng Sun
- The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, PR China
| | - Lu Song
- Department of Chemistry, Tsinghua University, Beijing 100084, PR China; The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
| | - Chunmei Gao
- The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
| | - Feng Liu
- The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.
| | - Yuzong Chen
- National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Bioinformatics and Drug Design Group, Department of Pharmacy, Centre for Computational Science and Engineering, National University of Singapore, 117543, Singapore
| | - Yuyang Jiang
- The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China.
| |
Collapse
|
82
|
Affiliation(s)
- Hai Huang
- Department of Chemistry and
Biochemistry, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154-4003, United States
| | - Jun Yong Kang
- Department of Chemistry and
Biochemistry, University of Nevada Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada 89154-4003, United States
| |
Collapse
|
83
|
Reis J, Gaspar A, Milhazes N, Borges F. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. J Med Chem 2017; 60:7941-7957. [PMID: 28537720 DOI: 10.1021/acs.jmedchem.6b01720] [Citation(s) in RCA: 218] [Impact Index Per Article: 31.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The use of privileged structures in drug discovery has proven to be an effective strategy, allowing the generation of innovative hits/leads and successful optimization processes. Chromone is recognized as a privileged structure and a useful template for the design of novel compounds with potential pharmacological interest, particularly in the field of neurodegenerative, inflammatory, and infectious diseases as well as diabetes and cancer. This perspective provides the reader with an update of an earlier article entitled "Chromone: A Valid Scaffold in Medicinal Chemistry" ( Chem. Rev. 2014 , 114 , 4960 - 4992 ) and is mainly focused on chromones of biological interest, including those isolated from natural sources. Moreover, as drug repurposing is becoming an attractive drug discovery approach, recent repurposing studies of chromone-based drugs are also reported.
Collapse
Affiliation(s)
- Joana Reis
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| | - Alexandra Gaspar
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| | - Nuno Milhazes
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| | - Fernanda Borges
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto , Porto 4169-007, Portugal
| |
Collapse
|
84
|
Hendriks CM, Hartkamp J, Wiezorek S, Steinkamp AD, Rossetti G, Lüscher B, Bolm C. Sulfoximines as ATR inhibitors: Analogs of VE-821. Bioorg Med Chem Lett 2017; 27:2659-2662. [DOI: 10.1016/j.bmcl.2017.04.026] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 04/07/2017] [Accepted: 04/07/2017] [Indexed: 10/19/2022]
|
85
|
Zhan M, Deng Y, Zhao L, Yan G, Wang F, Tian Y, Zhang L, Jiang H, Chen Y. Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors. J Med Chem 2017; 60:4023-4035. [PMID: 28409639 DOI: 10.1021/acs.jmedchem.7b00357] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Dysfunctional signaling of the PI3K/AKT/mTOR pathway in cancer and its crucial role in cell growth and survival have made it a much desired target for cancer therapeutics. A series of dimorpholine substituted thienopyrimidine derivatives had been prepared and evaluated in vitro and in vivo. Among them, compound 14o was identified as a dual Class I PI3K and mTOR kinase inhibitor, which had an approximately 8-fold improvement in mTOR inhibition relative to the class I PI3K inhibitor 1 (pictilisib, GDC-0941). Western blot analysis confirmed the 14o mechanistic modulation of the cellular PI3K/AKT/mTOR pathway through inhibiting phosphorylation of both AKT and S6 in human cancer cell lines. In addition, 14o demonstrated significant efficacy in SKOV-3 and U87MG tumor xenograft models without causing significant weight loss and toxicity.
Collapse
Affiliation(s)
- Miao Zhan
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Yufang Deng
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Lifeng Zhao
- Sichuan Industrial Institute of Antibiotics, Chengdu University , Chengdu 610052, China
| | - Guoyi Yan
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Fangying Wang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Ye Tian
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Lanxi Zhang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Hongxia Jiang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Yuanwei Chen
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China.,Hinova Pharmaceuticals Inc. , Suite 402, Building B, #5 South KeYuan Road, Chengdu, 610041, China
| |
Collapse
|
86
|
|
87
|
War JA, Srivastava SK, Srivastava SD. Design, synthesis and DNA-binding study of some novel morpholine linked thiazolidinone derivatives. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2017; 173:270-278. [PMID: 27673496 DOI: 10.1016/j.saa.2016.07.054] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 07/29/2016] [Accepted: 07/31/2016] [Indexed: 06/06/2023]
Abstract
The emergence of multiple drug resistance amongst bacterial strains resulted in many clinical drugs to be ineffective. Being vulnerable to bacterial infections any lack in the development of new antimicrobial drugs could pose a serious threat to public health. Here we report design and synthesis of a novel class of morpholine linked thiazolidinone hybrid molecules. The compounds were characterized by FT-IR, NMR and HRMS techniques. Susceptibility tests showed that most of the synthesized molecules were highly active against multiple bacterial strains. Compound 3f displayed MIC values which were better than the standard drug for most of the tested strains. DNA being a well defined target for many antimicrobial drugs was probed as possible target for these synthetic molecules. DNA-binding study of 3f with sm-DNA was probed through UV-vis absorption, fluorescence quenching, gel electrophoresis and molecular docking techniques. The studies revealed that compound 3f has strong affinity towards DNA and binds at the minor groove. The docking studies revealed that the compound 3f shows preferential binding towards A/T residues.
Collapse
Affiliation(s)
- Javeed Ahmad War
- Synthetic Organic Chemistry & Molecular Modelling Laboratory, Department of Chemistry, Dr. Hari Singh Gour Central University, Sagar, MP 470003, India
| | - Santosh Kumar Srivastava
- Synthetic Organic Chemistry & Molecular Modelling Laboratory, Department of Chemistry, Dr. Hari Singh Gour Central University, Sagar, MP 470003, India.
| | - Savitri Devi Srivastava
- Synthetic Organic Chemistry & Molecular Modelling Laboratory, Department of Chemistry, Dr. Hari Singh Gour Central University, Sagar, MP 470003, India
| |
Collapse
|
88
|
Huang H, Kang JY. Oxidation-Reduction Condensation of Diazaphosphites for Carbon-Heteroatom Bond Formation Based on Mitsunobu Mechanism. Org Lett 2017; 19:544-547. [PMID: 28107019 DOI: 10.1021/acs.orglett.6b03709] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
An efficient oxidation-reduction condensation reaction of diazaphosphites with various nonacidic pronucleophiles in the presence of DIAD as a weak oxidant has been developed for carbon-heteroatom bond formation. This mild process affords structurally diverse tertiary amines, secondary amines, esters, ethers, and thioethers in moderate to excellent yields. The selective synthesis of secondary amines from primary amines has been achieved. Importantly, a practical application to the synthesis of antiparkinsonian agent piribedil has been demonstrated.
Collapse
Affiliation(s)
- Hai Huang
- Department of Chemistry and Biochemistry, University of Nevada Las Vegas , 4505 South Maryland Parkway, Las Vegas, Nevada 89154-4003, United States.,Department of Applied Chemistry, College of Chemistry and Molecular Engineering, Nanjing Tech University , No. 30 Puzhu Road (S), Nanjing 211816, People's Republic of China
| | - Jun Yong Kang
- Department of Chemistry and Biochemistry, University of Nevada Las Vegas , 4505 South Maryland Parkway, Las Vegas, Nevada 89154-4003, United States
| |
Collapse
|
89
|
Champiré A, Vala C, Laabid A, Benharref A, Marchivie M, Plé K, Routier S. Controlled Dimroth Rearrangement in the Suzuki-Miyaura Cross Coupling of Triazolopyridopyrimidines. J Org Chem 2016; 81:12506-12513. [PMID: 27978739 DOI: 10.1021/acs.joc.6b02357] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Polynitrogen heterocycles are often subject to Dimroth rearrangement which consists of ring opening, bond rotation, and ring closure. In this note, we report a synthesis of two new families of triazolopyridopyrimidines. Successful functionalization via a Suzuki-Miyaura coupling was performed with total control of triazole (Dimroth) isomerization based on the judicious choice of reaction conditions.
Collapse
Affiliation(s)
- Anthony Champiré
- Institut de Chimie Organique et Analytique (ICOA) UMR 7311, University of Orléans, CNRS , BP 6759, Orléans F-45067, France
| | - Christine Vala
- Institut de Chimie Organique et Analytique (ICOA) UMR 7311, University of Orléans, CNRS , BP 6759, Orléans F-45067, France
| | - Achraf Laabid
- Institut de Chimie Organique et Analytique (ICOA) UMR 7311, University of Orléans, CNRS , BP 6759, Orléans F-45067, France.,Faculty of Sciences Semlalia, Cadi Ayyad University , BP 2390, Marrakech 40000, Morocco
| | - Ahmed Benharref
- Faculty of Sciences Semlalia, Cadi Ayyad University , BP 2390, Marrakech 40000, Morocco
| | - Mathieu Marchivie
- CNRS, University of Bordeaux, ICMCB, UPR 9048 , Pessac F-33600, France
| | - Karen Plé
- Institut de Chimie Organique et Analytique (ICOA) UMR 7311, University of Orléans, CNRS , BP 6759, Orléans F-45067, France
| | - Sylvain Routier
- Institut de Chimie Organique et Analytique (ICOA) UMR 7311, University of Orléans, CNRS , BP 6759, Orléans F-45067, France
| |
Collapse
|
90
|
Cansfield AD, Ladduwahetty T, Sunose M, Ellard K, Lynch R, Newton AL, Lewis A, Bennett G, Zinn N, Thomson DW, Rüger AJ, Feutrill JT, Rausch O, Watt AP, Bergamini G. CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model. ACS Med Chem Lett 2016; 7:768-73. [PMID: 27563401 DOI: 10.1021/acsmedchemlett.6b00149] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 06/10/2016] [Indexed: 12/20/2022] Open
Abstract
CZ415, a potent ATP-competitive mTOR inhibitor with unprecedented selectivity over any other kinase is described. In addition to a comprehensive characterization of its activities in vitro, in vitro ADME, and in vivo pharmacokinetic data are reported. The suitability of this inhibitor for studying in vivo mTOR biology is demonstrated in a mechanistic mouse model monitoring mTOR proximal downstream phosphorylation signaling. Furthermore, the compound reported here is the first ATP-competitive mTOR inhibitor described to show efficacy in a semitherapeutic collagen induced arthritis (CIA) mouse model.
Collapse
Affiliation(s)
- Andrew D. Cansfield
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Tammy Ladduwahetty
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Mihiro Sunose
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Katie Ellard
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Rosemary Lynch
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Anthea L. Newton
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Ann Lewis
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Gavin Bennett
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Nico Zinn
- Cellzome AG, Meyerhofstraße
1, 69117 Heidelberg, Germany
| | | | - Anne J. Rüger
- Cellzome AG, Meyerhofstraße
1, 69117 Heidelberg, Germany
| | - John T. Feutrill
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Oliver Rausch
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | - Alan P. Watt
- Cellzome Ltd, Chesterford Research
Park, Saffron Waldon, CB10
1XL, United Kingdom
| | | |
Collapse
|
91
|
Synthesis, structures elucidation, DNA-PK, PI3K and antiplatelet activity of a series of novel 7- or 8-(N-substituted)-2-morpholino-quinazolines. Med Chem Res 2016. [DOI: 10.1007/s00044-016-1608-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
92
|
Senwar KR, Reddy TS, Thummuri D, Sharma P, Bharghava SK, Naidu V, Shankaraiah N. Design and synthesis of 4′-O-alkylamino-tethered-benzylideneindolin-2-ones as potent cytotoxic and apoptosis inducing agents. Bioorg Med Chem Lett 2016; 26:4061-9. [DOI: 10.1016/j.bmcl.2016.06.077] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 06/24/2016] [Accepted: 06/27/2016] [Indexed: 12/22/2022]
|
93
|
Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents. Eur J Med Chem 2016; 118:34-46. [DOI: 10.1016/j.ejmech.2016.04.025] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Revised: 03/03/2016] [Accepted: 04/08/2016] [Indexed: 01/01/2023]
|
94
|
Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, Johnson J, Redman A, Robbins AH, Esler W, Fracasso RP, Garrison T, Hamilton M, Michels M, Wood JE, Wilkie DP, Xiao H, Levy J, Stasik E, Liu N, Schaefer M, Brands M, Lefranc J. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). ChemMedChem 2016; 11:1517-30. [PMID: 27310202 PMCID: PMC5094563 DOI: 10.1002/cmdc.201600148] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 05/12/2016] [Indexed: 12/12/2022]
Abstract
The phosphoinositide 3‐kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers. As such, the development of PI3K inhibitors from novel compound classes should lead to differential pharmacological and pharmacokinetic profiles and allow exploration in various indications, combinations, and dosing regimens. A screening effort aimed at the identification of PI3Kγ inhibitors for the treatment of inflammatory diseases led to the discovery of the novel 2,3‐dihydroimidazo[1,2‐c]quinazoline class of PI3K inhibitors. A subsequent lead optimization program targeting cancer therapy focused on inhibition of PI3Kα and PI3Kβ. Herein, initial structure–activity relationship findings for this class and the optimization that led to the identification of copanlisib (BAY 80‐6946) as a clinical candidate for the treatment of solid and hematological tumors are described.
Collapse
Affiliation(s)
- William J Scott
- Global Development, Global Program Management, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, 07981, USA.
| | | | - R Bruce Rowley
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Cathy O Bull
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Susan Jenkins
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Ann M Bullion
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | | | - Anikó Redman
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | | | - William Esler
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | | | | | - Mark Hamilton
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Martin Michels
- Global Drug Discovery, Project Management Drug Discovery, Bayer Pharma AG, 13353, Berlin, Germany
| | - Jill E Wood
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Dean P Wilkie
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Hong Xiao
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Joan Levy
- Former Bayer Research Center, West Haven, CT, 16516, USA
| | - Enrico Stasik
- Global Drug Discovery, TRG Oncology, Bayer Pharma AG, 13353, Berlin, Germany
| | - Ningshu Liu
- Global Drug Discovery, TRG Oncology, Bayer Pharma AG, 13353, Berlin, Germany
| | - Martina Schaefer
- Global Drug Discovery, Structural Biology, Bayer Pharma AG, 13353, Berlin, Germany
| | - Michael Brands
- Global Drug Discovery, Medicinal Chemistry Berlin, Bayer Pharma AG, 13353, Berlin, Germany
| | - Julien Lefranc
- Global Drug Discovery, Medicinal Chemistry Berlin, Bayer Pharma AG, 13353, Berlin, Germany.
| |
Collapse
|
95
|
Morrison R, Al-Rawi JMA. Synthesis, structure elucidation, DNA-PK, PI3K, anti-platelet and anti-bacteria activity of linear 5, 6, and 10-substituted-2-morpholino-chromen-oxazine-dione and angular 3, 4, 6-substituted-8-morpholino-chromen-oxazine-2,10-dione. J Enzyme Inhib Med Chem 2016; 31:86-95. [PMID: 27255290 DOI: 10.1080/14756366.2016.1190710] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Coumarin, a naturally occurring or synthesised phytochemical, displays a wide range of biological activities. However, chromen-2-ones fused with 1,3-benzoxazine rings is not well documented and there is a gap in the literature which required engaging. The substituted-2-thioxo-chromen-oxazine linear compounds 14a-i and angular compounds 16a-e were synthesised from the reaction of hydroxy-substituted-chromene-carboxylic 10-13 with freshly prepared Ph3P(SCN)2. 2-Morpholino-substituted-chromen-oxazine-4,8-dione and 8-morpholino-substituted-chromen-oxazine-2,10-dione 15a-f and 17 were synthesised from the reaction of the corresponding oxazines 14 and 16 with morpholine. PI3K activity was observed for the hydroxy-substituted-chromene-carboxylic acid of which compound 13b showed moderate PI3Kγ (IC50 = 5.56 μM) and PI3Kα (IC50 = 14.7 μM) activity. Additionally, 8-morpholino-chromen-oxazine-2,10-dione 17a showed isoform selective PI3Kδ activity with IC50 = 5.08 μM with non-DNA-PK ≥ 100 μM. Consequently compound 17a can be considered as a selective PI3Kδ inhibitor with non-DNA-PK at compound concentrations ≥100 μM.
Collapse
Affiliation(s)
- Rick Morrison
- a Pharmacy and Applied Science, La Trobe Institute for Molecular Science, La Trobe University , Bendigo , VIC , Australia
| | - Jasim M A Al-Rawi
- a Pharmacy and Applied Science, La Trobe Institute for Molecular Science, La Trobe University , Bendigo , VIC , Australia
| |
Collapse
|
96
|
Chen Y, Wang X, Xiang W, He L, Tang M, Wang F, Wang T, Yang Z, Yi Y, Wang H, Niu T, Zheng L, Lei L, Li X, Song H, Chen L. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. J Med Chem 2016; 59:5488-504. [PMID: 27186676 DOI: 10.1021/acs.jmedchem.6b00579] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized. Several compounds demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines. Among them, compound 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties. Western blot analysis further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concentration in vitro. In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body weight and toxicity. All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematological cancer.
Collapse
Affiliation(s)
- Yong Chen
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China.,School of Chemical Engineering, Sichuan University , Chengdu, 610065, China
| | - Xiaoyan Wang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Wei Xiang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Lin He
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Minghai Tang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Fang Wang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Taijin Wang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Zhuang Yang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Yuyao Yi
- Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Hairong Wang
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Ting Niu
- Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Li Zheng
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Lei Lei
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Xiaobin Li
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| | - Hang Song
- School of Chemical Engineering, Sichuan University , Chengdu, 610065, China
| | - Lijuan Chen
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University , Chengdu, 610041, China
| |
Collapse
|
97
|
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. Future Med Chem 2016; 7:873-91. [PMID: 26061106 DOI: 10.4155/fmc.15.33] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
In this article, we review the ATR inhibitor field from initial pharmacological tools to first-generation clinical candidates with the potential to bring benefit to cancer patients. ATR is a critical part of the cell DNA-damage response. Over the past decade or more, compounds with weak ATR potency and low specificity have been used as tools in early studies to elucidate ATR pharmacology. More recently highly potent, selective and in vivo active ATR inhibitors have been developed enabling detailed preclinical in vitro and in vivo target assessment to be made. The published studies reveal the potential of ATR inhibitors for use as monotherapy or in combination with DNA-damaging agents. To date, VX-970 and AZD6738, have entered clinical assessment.
Collapse
|
98
|
Yousuf I, Arjmand F, Tabassum S, Toupet L, Khan RA, Siddiqui MA. Mechanistic insights into a novel chromone-appended Cu(II) anticancer drug entity: in vitro binding profile with DNA/RNA substrates and cytotoxic activity against MCF-7 and HepG2 cancer cells. Dalton Trans 2016; 44:10330-42. [PMID: 25970097 DOI: 10.1039/c5dt00770d] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A new chromone-appended Cu(ii) drug entity () was designed and synthesized as a potential anticancer chemotherapeutic agent. The structural elucidation was carried out thoroughly by elemental analysis, FT-IR, EPR, ESI-MS and single crystal X-ray crystallography. Complex resulted from the in situ methoxylation reaction of the 3-formylchromone ligand and its subsequent complexation with the copper nitrate salt in a 2 : 1 ratio, respectively. crystallized in the monoclinic P21/c space group possessing the lattice parameters, a = 8.75 Å, b = 5.07 Å, c = 26.22 Å, α = γ = 90°, β = 96.3° per unit cell. Furthermore, in vitro interaction studies of with ct-DNA and tRNA were carried out which suggested more avid binding propensity towards the RNA target via intercalative mode, which was reflected from its Kb, K and Ksv values. The gel electrophoretic mobility assay was carried out on the pBR322 plasmid DNA substrate, to ascertain the cleaving ability and the mechanistic pathway in the presence of additives, and the results revealed the efficient cleaving ability of via the oxidative pathway. In vitro cell growth inhibition via the MTT assay was carried out to evaluate the cytotoxicity of complex and IC50 values were found to be in the range of 5-10 μg mL(-1) in HepG2 and MCF-7 cancer cell lines, which were found to be much lower than the IC50 values of previously reported similar Cu(ii) complexes. Additionally, in the presence of , reactive oxygen species (ROS) and thiobarbituric acid reactive substance (TBARS) levels in the tested cancer cell lines increased significantly, coupled with reduced glutathione (GSH) levels. Thus, our results suggested that ROS plays an important role in cell apoptosis induced by the Cu(ii) complex and validates its potential to act as a robust anticancer drug entity.
Collapse
Affiliation(s)
- Imtiyaz Yousuf
- Department of Chemistry, Aligarh Muslim University, Aligarh 202002, India.
| | | | | | | | | | | |
Collapse
|
99
|
Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016; 160:65-83. [PMID: 26896565 DOI: 10.1016/j.pharmthera.2016.02.003] [Citation(s) in RCA: 258] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The repair of DNA damage is a complex process that relies on particular pathways to remedy specific types of damage to DNA. The range of insults to DNA includes small, modest changes in structure including mismatched bases and simple methylation events to oxidized bases, intra- and interstrand DNA crosslinks, DNA double strand breaks and protein-DNA adducts. Pathways required for the repair of these lesions include mismatch repair, base excision repair, nucleotide excision repair, and the homology directed repair/Fanconi anemia pathway. Each of these pathways contributes to genetic stability, and mutations in genes encoding proteins involved in these pathways have been demonstrated to promote genetic instability and cancer. In fact, it has been suggested that all cancers display defects in DNA repair. It has also been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. This has led to targeting DNA repair pathways and proteins to develop anti-cancer agents that will increase sensitivity to traditional chemotherapeutics. While initial studies languished and were plagued by a lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interaction and develop high affinity chemical inhibitors have proven considerably more effective. In this review we will highlight recent advances and discuss previous failures in targeting DNA repair to pave the way for future DNA repair targeted agents and their use in cancer therapy.
Collapse
Affiliation(s)
- Navnath S Gavande
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States
| | | | - Hilary D Hinshaw
- Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, United States
| | - Shadia I Jalal
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States
| | - Catherine R Sears
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States
| | | | - John J Turchi
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States; NERx Biosciences, Indianapolis, IN 46202, United States; Department of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
| |
Collapse
|
100
|
Zaytsev AV, Pickles JE, Harnor SJ, Henderson AP, Alyasiri M, Waddell PG, Cano C, Griffin RJ, Golding BT. Concise syntheses of bridged morpholines. RSC Adv 2016. [DOI: 10.1039/c6ra08737j] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Practical syntheses of 8-oxa-3-aza-bicyclo[3.2.1]octane and 9-oxa-3-aza-bicyclo[3.3.1]nonane, useful intermediates for synthesising kinase inhibitors, were achieved from readily available starting materials, using a solvent-free thermolytic cyclisation for the key step.
Collapse
Affiliation(s)
| | - James E. Pickles
- Newcastle Cancer Centre
- Northern Institute for Cancer Research
- School of Chemistry
- Newcastle University
- Newcastle upon Tyne
| | - Suzannah J. Harnor
- Newcastle Cancer Centre
- Northern Institute for Cancer Research
- School of Chemistry
- Newcastle University
- Newcastle upon Tyne
| | | | - Mohammed Alyasiri
- Newcastle Cancer Centre
- Northern Institute for Cancer Research
- School of Chemistry
- Newcastle University
- Newcastle upon Tyne
| | - Paul G. Waddell
- School of Chemistry
- Newcastle University
- Newcastle upon Tyne
- UK
| | - Celine Cano
- Newcastle Cancer Centre
- Northern Institute for Cancer Research
- School of Chemistry
- Newcastle University
- Newcastle upon Tyne
| | - Roger J. Griffin
- Newcastle Cancer Centre
- Northern Institute for Cancer Research
- School of Chemistry
- Newcastle University
- Newcastle upon Tyne
| | - Bernard T. Golding
- NewChem Technologies Ltd
- Whitesmocks
- UK
- Newcastle Cancer Centre
- Northern Institute for Cancer Research
| |
Collapse
|